[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019013053A - Composicion que contiene ciclodextrina y busulfan. - Google Patents

Composicion que contiene ciclodextrina y busulfan.

Info

Publication number
MX2019013053A
MX2019013053A MX2019013053A MX2019013053A MX2019013053A MX 2019013053 A MX2019013053 A MX 2019013053A MX 2019013053 A MX2019013053 A MX 2019013053A MX 2019013053 A MX2019013053 A MX 2019013053A MX 2019013053 A MX2019013053 A MX 2019013053A
Authority
MX
Mexico
Prior art keywords
busulfan
composition containing
containing cyclodextrin
cyclodextrin
formulation
Prior art date
Application number
MX2019013053A
Other languages
English (en)
Inventor
D Pipkin James
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of MX2019013053A publication Critical patent/MX2019013053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen formulaciones farmacéuticas que contienen busulfán y ciclodextrina. La formulación puede incluir busulfán y ciclodextrina en una solución acuosa clara. También se describen un proceso para preparar la formulación de busulfán y método para utilizar la formulación.
MX2019013053A 2017-05-03 2018-05-02 Composicion que contiene ciclodextrina y busulfan. MX2019013053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500970P 2017-05-03 2017-05-03
PCT/US2018/030728 WO2018204535A1 (en) 2017-05-03 2018-05-02 Composition containing cyclodextrin and busulfan

Publications (1)

Publication Number Publication Date
MX2019013053A true MX2019013053A (es) 2020-02-07

Family

ID=64014433

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013053A MX2019013053A (es) 2017-05-03 2018-05-02 Composicion que contiene ciclodextrina y busulfan.
MX2023000348A MX2023000348A (es) 2017-05-03 2019-11-01 Composicion que contiene ciclodextrina y busulfan.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000348A MX2023000348A (es) 2017-05-03 2019-11-01 Composicion que contiene ciclodextrina y busulfan.

Country Status (10)

Country Link
US (2) US20180318249A1 (es)
EP (1) EP3618825A4 (es)
JP (2) JP7204670B2 (es)
KR (1) KR20190141244A (es)
CN (1) CN110831588B (es)
AU (1) AU2018263924B2 (es)
BR (1) BR112019023074A2 (es)
CA (1) CA3062308A1 (es)
MX (2) MX2019013053A (es)
WO (1) WO2018204535A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用
CN113679852B (zh) * 2021-09-13 2022-11-15 天津师范大学 一种水溶性主客体复合物及其制备与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1991018022A1 (fr) 1990-05-21 1991-11-28 Toppan Printing Co., Ltd. Derive de cyclodextrine
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5430057A (en) 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE69834154T2 (de) 1997-07-01 2007-01-25 Pfizer Products Inc., Groton Verfahren zur Herstellung von einem Cyclodextrin
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
CA2495899A1 (en) 2002-08-15 2004-03-18 Yunqing Liu Solid nano pharmaceutical formulation and preparation method thereof
JP2006503047A (ja) 2002-09-13 2006-01-26 サイデックス・インコーポレイテッド 誘導シクロデキストリンにより安定化された水性フィル組成物を含有するカプセル
CA2543443A1 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
JP5465432B2 (ja) 2005-10-26 2014-04-09 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物及びその製造方法
CA2631014C (en) 2005-11-28 2015-04-28 Vernon D. Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
PL2434886T3 (pl) * 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
KR20190137963A (ko) * 2012-05-08 2019-12-11 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
CN105726467A (zh) * 2014-12-09 2016-07-06 四川科瑞德制药有限公司 一种白消安注射液及其制备方法

Also Published As

Publication number Publication date
JP2020518608A (ja) 2020-06-25
BR112019023074A2 (pt) 2020-06-09
MX2023000348A (es) 2023-02-13
EP3618825A4 (en) 2021-01-20
WO2018204535A1 (en) 2018-11-08
US20230255919A1 (en) 2023-08-17
AU2018263924B2 (en) 2024-07-04
RU2019135196A (ru) 2021-06-03
JP2023026562A (ja) 2023-02-24
CN110831588B (zh) 2023-06-27
AU2018263924A1 (en) 2019-11-21
EP3618825A1 (en) 2020-03-11
US20180318249A1 (en) 2018-11-08
KR20190141244A (ko) 2019-12-23
RU2019135196A3 (es) 2021-07-28
CN110831588A (zh) 2020-02-21
JP7204670B2 (ja) 2023-01-16
CA3062308A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2017000026A (es) Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
WO2016007617A3 (en) Pharmaceutical compounding kit
CL2015002387A1 (es) Nuevos derivados de pirazol.
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
MY192532A (en) Liquid pharmaceutical composition
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
EP3342858A4 (en) ROR1-POSITIVE MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES USING SAID ROR1 POSITIVE MESENCHYMAL STEM CELLS
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
MX2017003121A (es) Formulaciones de anticuerpos.
WO2016001905A3 (en) Stable liquid ready-to-use injectable formulation of bortezomib
EP3225620A4 (en) Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition containing same
EA201691741A1 (ru) Фармацевтическая композиция
MX2023000348A (es) Composicion que contiene ciclodextrina y busulfan.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP3679919A4 (en) SKIN OR HAIR CLEANSING COMPOSITION WITH AN AQUATIC GELLING AGENT AND PROCESS FOR THE PREPARATION OF AN AQUATIC GELLING AND DETERGENT COMPOSITION
BR112017022523A2 (pt) ?formulação para cápsulas de gel, cápsula de gel, e, processo?.
MX2019002921A (es) Composiciones para el cuidado bucal y sistema para dispensar las mismas.
SG11201901617PA (en) Azole compound ophthalmic preparation
PH12018502139A1 (en) Phosphaplatin liquid formulations